Published in Dermatopathology (Basel) on January 09, 2014
Small-sample estimation of negative binomial dispersion, with applications to SAGE data. Biostatistics (2007) 18.19
Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res (2003) 3.07
Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev (1999) 2.77
Clinical practice. Vitiligo. N Engl J Med (2009) 2.72
High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med (1998) 2.58
Pathogenesis of oral lichen planus--a review. J Oral Pathol Med (2010) 2.16
Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol (2012) 2.02
Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res (2003) 1.90
Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol (1991) 1.89
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81
Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71
HLA alleles and amino-acid signatures of the peptide-binding pockets of HLA molecules in vitiligo. J Invest Dermatol (2011) 1.68
Ulcerative colitis, myasthenia gravis, atypical lichen planus, alopecia areata, vitiligo. Proc R Soc Med (1974) 1.65
Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology (2001) 1.60
New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res (2002) 1.42
Autoimmune aspects of vitiligo. Autoimmunity (2001) 1.30
Oxidative stress in lichen planus. Acta Dermatovenerol Alp Pannonica Adriat (2010) 1.26
Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol (1997) 1.22
4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol (2005) 1.20
CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J Invest Dermatol (2001) 1.18
CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol (2010) 1.16
Identification of intergenic trans-regulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders. Cell Cycle (2009) 1.16
Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol (1991) 1.15
Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol (2011) 1.15
Serum selenium levels and blood glutathione peroxidase activities in vitiligo. Br J Dermatol (1999) 1.11
Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol (2011) 1.08
Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation. J Invest Dermatol (2012) 1.07
Physiopathology and genetics of vitiligo. J Autoimmun (2005) 1.05
Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism. Dermatology (1995) 1.04
Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol (1997) 1.04
Disordered pigmentation, spastic paraparesis and peripheral neuropathy in three siblings: a new neurocutaneous syndrome. J Neurol Neurosurg Psychiatry (1980) 1.02
Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One (2012) 1.01
Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol (2006) 1.00
Oxidative stress and autoimmune skin disease. Eur J Dermatol (2013) 0.99
Higher plasma catecholamine and metabolite levels in the early phase of nonsegmental vitiligo. Pigment Cell Res (2000) 0.98
Health-related quality of life and marital quality of vitiligo patients in China. J Eur Acad Dermatol Venereol (2011) 0.97
Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol (1993) 0.97
Impaired PI3K/Akt activation-mediated NF-kappaB inactivation under elevated TNF-alpha is more vulnerable to apoptosis in vitiliginous keratinocytes. J Invest Dermatol (2007) 0.95
Epidermal H(2)O(2) accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: identification of a general mechanism in regulation of all 6BH4-dependent processes? J Invest Dermatol (2001) 0.94
White patches and bruised souls: advances in the pathogenesis and treatment of vitiligo. J Am Acad Dermatol (2004) 0.93
Hyaluronic acid enhances cell proliferation during eosinopoiesis through the CD44 surface antigen. J Immunol (1995) 0.91
Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol (2004) 0.91
Enhancement of both long-term depression induction and optokinetic response adaptation in mice lacking delphilin. PLoS One (2008) 0.91
Quality of life in patients with vitiligo: a descriptive study on 83 patients attending a PUVA therapy unit in Imam Reza Hospital, Mashad. Indian J Dermatol Venereol Leprol (2010) 0.91
Inflammasome-mediated autoinflammatory disorders. Postgrad Med (2010) 0.90
Catecholamines and vitiligo. Pigment Cell Res (1992) 0.90
Characterization of the delta2 glutamate receptor-binding protein delphilin: Splicing variants with differential palmitoylation and an additional PDZ domain. J Biol Chem (2006) 0.90
Role of keratinocytes in the development of vitiligo. Ann Dermatol (2012) 0.89
The involvement of Smac/DIABLO, p53, NF-kB, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: Protective effects of curcumin and capsaicin. Antioxid Redox Signal (2010) 0.88
Glycoconjugate profile and CD44 expression in human melanoma cell lines with different metastatic capacity. Int J Cancer (1995) 0.87
Muscle inflammation, autoimmune Addison's disease and sarcoidosis in a patient with dysferlin deficiency. Neuromuscul Disord (2006) 0.87
Becker nevus with vitiligo and lichen planus: Cocktail of dermatoses. N Am J Med Sci (2010) 0.86
Multiple paraneoplastic syndromes: myasthenia gravis, vitiligo, alopecia areata, and oral lichen planus associated with thymoma. J Neurol Sci (2011) 0.86
Vitiligo. Acta Dermatovenerol Alp Pannonica Adriat (2005) 0.86
Targeting skin: vitiligo and autoimmunity. J Invest Dermatol (2012) 0.85
Relationship between levels of soluble interleukin-2 receptors and the types and activity of vitiligo. J Dermatol (1997) 0.83
Mesocortical dopamine and HPA axis regulation: role of laterality and early environment. Brain Res (2006) 0.83
Myosin VI regulates actin dynamics and melanosome biogenesis. Traffic (2012) 0.83
Lack of association between catalase gene polymorphism (T/C exon 9) and susceptibility to vitiligo in a Turkish population. Genet Mol Res (2011) 0.82
Decreased proinflammatory cytokine production by peripheral blood mononuclear cells from vitiligo patients following aspirin treatment. Saudi Med J (2005) 0.82
The mRNA expression profile of cytokines connected to the regulation of melanocyte functioning in vitiligo skin biopsy samples and peripheral blood mononuclear cells. Hum Immunol (2012) 0.82
Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral centre. Br J Dermatol (2009) 0.82
Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases. Mediators Inflamm (2012) 0.80
Pathophysiology of vitiligo. Clin Dermatol (1998) 0.80
Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report. Eur J Neurol (2009) 0.79
Vitiligo-spasticity syndrome: new case. Clin Dysmorphol (2003) 0.79
Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci (1999) 0.79
Serum levels of functional T-regs in vitiligo: our experience and mini-review of the literature. Eur J Dermatol (2013) 0.77
MicroRNA expression profiling identifies potential serum biomarkers for non-segmental vitiligo. Pigment Cell Melanoma Res (2013) 0.77
Thymoma accompanied by lichen planus. Interact Cardiovasc Thorac Surg (2007) 0.76
Analysis of the expression profile of CRH-POMC system genes in vitiligo skin biopsies. J Dermatol Sci (2010) 0.76
Muscle regeneration and inflammation in patients with facioscapulohumeral muscular dystrophy. Acta Neurol Scand (2013) 0.76
Facioscapulohumeral dystrophy with myositis associated with rheumatoid arthritis. Clin Rheumatol (1996) 0.76
Vitiligo: recent insights and new therapeutic approaches. G Ital Dermatol Venereol (2012) 0.76